Evidence map›Paper›PMID 10761709›Full record

ArticleJapanese journal of cancer research : Gann2000

Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells.

C M Tsai, K T Chang, L Li, R P Perng, L Y Yang

Open access · bronzeAbstract read
In one paragraph

Article in Japanese journal of cancer research : Gann, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

C M TsaiChest Department, Veterans General Hospital-Taipei, Shih-pai, Taiwan. cmtsai@vghtpe.gov.tw
K T Chang
L Li
R P Perng
L Y Yang
National Yang Ming Chiao Tung University · TWThe University of Texas MD Anderson Cancer Center · USTaipei Veterans General Hospital · TW

Funding

DNA REPAIR INHIBITION TO IMPROVE LEUKEMIA THERAPYR29CA068137 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI YANG, LI-YING K · 1995 to 1999
–
NCI NIH HHS CA-68137
6 · The paper itself

Abstract

Nucleotide excision repair (NER) is a major repair mechanism for DNA lesions induced by cisplatin. Overexpressions of epidermal growth factor receptor (EGFR) and HER-2/neu have been reported to affect the sensitivity of certain human cancer cells to cisplatin, presumably by modification of DNA repair activity through interference with NER. Using an in vitro repair assay, we investigated NER activity of cisplatin-induced DNA lesions in a panel of 16 non-small cell lung cancer (NSCLC) cell lines. The interrelationships between NER activity, cisplatin sensitivity, HER-2/neu expression and EGFR level, were also analyzed. The results showed that high NER activity was closely correlated with cisplatin resistance and high levels of HER-2/neu expression (P<0.05). Analysis of the relationships between EGFR level and each of the other three parameters revealed no statistically significant correlations (all P values were >0.05 by Spearman rank correlation), but a trend of association (all the values of proportion of accordance were > or =62.5% by using a 2x2 contingency table). These results suggest that NER activity may play an important role in the cisplatin resistance of NSCLC cells and there may be an association between enhanced NER activity and high levels of p185neu and probably EGFR in NSCLC cells. The finding that high levels of EGFR showed very little influence on the relationship between p185neu and cisplatin resistance suggests that EGFR may be a less crucial factor in modulating the chemoresistance of NSCLC cells when compared with HER-2/neu.

Indexed as

DNA RepairGenes, erbB-2Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCisplatinDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesErbB ReceptorsHumansLung NeoplasmsTumor Cells, CulturedAntineoplastic AgentsCisplatinErb-b2 Receptor Tyrosine KinasesErbB Receptors

Identifiers

PMID10761709
PMCPMC5926326
OpenAlexW2036102152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.